Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation

SummaryCompound epidermal growth factor receptor (EGFR) mutations are defined as double or multiple independent mutations of theEGFR tyrosine kinase domain (TKD), in which anEGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutation is identified together with a mutation of unclarified clinical significance. Lung adenocarcinoma with compoundEGFR mutation shows poor clinical response toEGFR-TKIs. Kobayashi et al. reported a non-small-cell lung cancer (NSCLC) patient whose tumor hadEGFR exon21 L858R/A871G mutation presented rapid disease progression to erlotinib. However, in this case, we present anEGFR exon21 L858R/A871G mutation patient exerted significant benefit to icotinib, another first-generationEGFR-TKI, indicating that differentEGFR-TKIs have diversiform sensitive sites and therapeutic effects, consistent mutation sites might achieve heterogeneous benefits from differentEGFR-TKIs. Our case report provides promisingEGFR-TKI for clinical treatment withEGFR exon21 L858R/A871G mutation in NSCLC. More dedicated efforts are needed to clarify their biologic effects on disease course and drug responsiveness.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research